NCT00257426View on ClinicalTrials.gov

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

September 30, 2009

Conditions
Liver Cancer
Interventions
DRUG

octreotide acetate

200mcg,3 times per day, 7 days per week, up to 36 weeks

Trial Locations (1)

27599

The University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00257426 - Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer | Biotech Hunter | Biotech Hunter